Answers are grounded in this paper and cite their sources.
Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.).
No takes yet. Share an insight, caveat, or question.
Paik et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: